Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 53

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 53
---
1, 2025, the number of shares of common stock available for issuance under the 2022 Plan increased by 1,627,955 shares, pursuant to these provisions. This increase is not reflected in the table above. |

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information regarding the ownership of our common stock as of March 27, 2025 by:

| ● | each of our named executive officers; |

| ● | each of our directors; and |

| ● | all of our current executive officers and directors as a group. |

At this time, there is no person or entity known by us to be the beneficial owners of more than five percent of our common stock. We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws. Applicable percentage ownership is based on 28,746,041 shares of common stock outstanding as of March 27, 2025. In computing the number of shares beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options or issuable pursuant to restricted stock units held by the person that are currently exercisable, or would vest or become exercisable based on service-based vesting conditions within 60 days of March 27, 2025. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o Gain Therapeutics, Inc., 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.

| ​                                                                      | ​ |                       ​ | ​ |                ​ | ​ |
| ​                                                                      |   | Beneficial Ownership(1) |   |                  |   |
| Name of Beneficial Owner                                               | ​ |        Number of Shares |   | Percent of Total | ​ |
| Named Executive Officers and Directors:                                | ​ |                       ​ |   |                ​ |   |
| Gene Mack(2)                                                           |   |                  68,566 |   |                * | ​ |
|